ARTICLE | Company News
Celtic Pharma, Neurobiological deal
September 26, 2005 7:00 AM UTC
Celtic acquired exclusive worldwide rights to Xerecept corticotropin-releasing factor from NTII. The synthetic human corticotropin-releasing factor (CRF) is in a Phase III trial to treat peritumoral ...